AMPICILLIN SULBACTAM RESISTANCE PATTERN AS A FIRST-LINE DRUG IN CHILDREN

First-line antiretroviral drug discontinuations in children

INTRODUCTION There are a limited number of paediatric antiretroviral drug options. Characterising the long term safety and durability of different antiretrovirals in children is important to optimise management of HIV infected children and to determine the estimated need for alternative drugs in paediatric regimens. We describe first-line antiretroviral therapy (ART) durability and reasons for ...

Minimal inhibitory concentrations of sulbactam/ampicillin against drug sensitive and drug resistant isolates of Mycobacterium tuberculosis.

A total of 92 isolates of Mycobacterium tuberculosis consisting of equal numbers of sensitive and resistant strains was tested for their susceptibility to sulbactam and ampicillin (in the ratio of 1:2) on Lowenstein-Jensen (LJ) and 7H11 agar media. The geometric mean MIC was 63.97 micrograms/ml for the drug sensitive strains and 65.92 micrograms/ml for the resistant strains, and the overall mea...

HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda

BACKGROUND There are limited data on primary human immunodeficiency virus drug resistance (HIVDR) in pediatric populations. This study aimed to assess the prevalence of primary HIVDR and associated risk factors among children initiating first-line antiretroviral therapy (ART) in Uganda. METHODS At three Ugandan clinics, children (age <12 years) requiring ART were recruited between January 201...

Pulmonary tuberculosis: Resistance pattern to first line anti-tuberculosis drugs

Pharmacokinetics of ampicillin and sulbactam in pediatric patients.

Intravenous ampicillin-sulbactam is effective in the treatment of various infections in adults, but little is known about the pharmacokinetics (PK) of ampicillin-sulbactam in children. The objective of this study was to determine the PK of ampicillin and sulbactam in pediatric patients with intra-abdominal infection, skin and/or skin structure infection, or periorbital-preseptal and facial cell...